Background
This long-term follow-up study from the St. Petersburg Institute of Bioregulation examined survival outcomes in a cohort of geriatric patients who received epitalon (or epithalamin) versus those who did not, over a 15-year observation period.
It represents the most ambitious longevity claim for epitalon with human data, and has been widely cited in longevity medicine discussions despite significant methodological limitations.
Methods
Retrospective cohort study. Elderly patients (aged 60–80 at enrollment) from a geriatric center tracked over 15 years. Treated group received epitalon 10 mg IM as periodic courses (typically 10 days, 1–2 times per year). Control group received standard care only.
Primary outcome: all-cause mortality.
Key Findings
| Group | N | 15-Year Survival | Mortality Reduction |
|---|---|---|---|
| Epitalon group | ~133 | ~72% | — |
| Control group | ~133 | ~55% | 28% RRR (reported) |
Additional findings: Treated group showed slower deterioration of immune function parameters (NK cell activity, T-cell counts) and endocrine markers (melatonin, cortisol rhythm).
Clinical Significance
A 28% reduction in all-cause mortality over 15 years, if validated, would represent one of the most significant longevity interventions ever documented. The authors attribute the effect to epitalon’s neuroendocrine normalization and anti-oxidative properties.
However, the study’s design limitations make it impossible to attribute the mortality difference to epitalon alone.
Limitations
- Non-randomized observational design; significant confounding risk
- Healthy user bias: patients who accepted treatment courses likely had better access to care and higher health literacy
- Dosing, compliance, and co-interventions not fully controlled
- All from a single research group with a clear interest in positive outcomes
- Not published in a high-impact journal with rigorous peer review
- No independent replication of survival data